TABLE 1.
All-cause mortality rates of 16 140 participants of NHANES III Aged >18 years, by anti-HCV and HCV RNA status
| Anti-HCV negative | Anti-HCV positive (RNA positive and negative) | Anti-HCV positive and HCV RNA positive (chronic HCV) | ||||
|---|---|---|---|---|---|---|
|
|
|
|
||||
| N | Mortality ratea (95% CI) | N | Mortality ratea (95% CI) | N | Mortality ratea (95% CI) | |
| All participants | 15 788 | 12.6 (11.6–13.7) | 352 | 17.0 (12.2–23.6) | 279 | 19.1 (13.5–27.0) |
|
| ||||||
| Men | ||||||
|
| ||||||
| Total | 7362 | 13.0 (11.9–14.2) | 212 | 15.2 (10.0–23.2) | 174 | 16.6 (10.6–26.1) |
|
| ||||||
| 18–29 y | 1798 | 2.3 (1.5–3.4) | 39 | 1.9 (0.7–5.7) | 33 | 2.4 (0.8–7.3) |
|
| ||||||
| 30–44 y | 1934 | 3.1 (2.4–3.9) | 104 | 12.0 (6.6–22.1) | 92 | 13.6 (7.2–25.8) |
|
| ||||||
| 45–59 y | 1255 | 13.7 (11.8–15.8) | 40 | 27.6 (13.8–55.2) | 31 | 43.4 (24.8–75.8) |
|
| ||||||
| ≥60 y | 2375 | 61.1 (56.4–66.2) | 29 | 150.3 (90.4–250.0) | 18 | 202.5 (108.6–377.8) |
|
| ||||||
| Women | ||||||
|
| ||||||
| Total | 8426 | 12.3 (11.1–13.5) | 140 | 20.3 (12.9–31.8) | 105 | 24.1 (15.1–38.2) |
|
| ||||||
| 18–29 y | 2071 | 1.3 (0.8–2.0) | 19 | 4.3 (1.2–16.1) | 13 | 3.8 (0.8–19.3) |
|
| ||||||
| 30–44 y | 2441 | 2.5 (1.8–3.3) | 69 | 7.6 (3.4–16.6) | 53 | 9.6 (4.2–22.0) |
|
| ||||||
| 45–59 y | 1418 | 9.8 (8.3–11.6) | 28 | 38.4 (21.3–69.3) | 21 | 44.4 (26.9–73.4) |
|
| ||||||
| ≥60 y | 2496 | 50.3 (46.7–54.1) | 24 | 82.2 (56.3–120.1) | 18 | 85.1 (48.8–148.3) |
a
Deaths per 1000 person-years.